RICHLAND, Wash., Sept. 28, 2016 /PRNewswire/ -- IsoRay, Inc.
(NYSE MKT: ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological
cancers, today announced the launch of its newly redesigned
corporate website at www.isoray.com.
The redesigned website introduces IsoRay's new branding and logo
and offers quick and easy access to essential information that
provides a comprehensive understanding of the Company's innovative
Cesium-131 products. It is both patient and clinician focused and
has an updated visual design and content structure which will make
it easier for patients and medical teams to find what they're
looking for. FAQ's are front and center for quick access to popular
questions. The website also has a comprehensive investor section
with updated company news and events, financial and stock
information, SEC filings and corporate governance
information. The Company's new branding was also
incorporated in physician materials at this week's American Society
for Radiation Oncology (Astro) Annual Meeting in Boston.
The site was built with a flexible content management system to
facilitate ongoing updates. Over time, more and more content will
be added including patient stories, clinician experiences and
peer-reviewed publications.
"The launch of IsoRay's new website, with our new branding and
logo, represents the patient and clinician focus of the Company
under the new management team," said Thomas
LaVoy, Chairman and CEO of IsoRay. "The robust
information it delivers for all of our constituencies is intended
to increase awareness of brachytherapy and its efficacy with
multiple cancers as well as provide a better understanding of the
benefits of IsoRay's innovative Cesium-131 patient solutions and
offer important resources to enable expanded use of our product
applications."
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is
the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more
about this innovative Richland,
Washington company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay.
Follow us on Twitter @IsoRay.
Safe Harbor Statement
Statements in this news release about IsoRay's future
expectations, including: the advantages of our products and their
delivery systems, whether interest in and use of our products will
increase or continue, whether the newly redesigned website will
increase patient or clinician engagement and interest, what content
will be included in future updates of the website, whether the FAQs
or other information provided address the concerns of the patient
or clinician, and all other statements in this release, other than
historical facts, are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
("PSLRA"). This statement is included for the express purpose of
availing IsoRay, Inc. of the protections of the safe harbor
provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from
those in such forward-looking statements based on such factors as
physician acceptance, training and use of our products, our ability
to successfully manufacture, market and sell our products, our
ability to manufacture our products in sufficient quantities to
meet demand within required delivery time periods while meeting our
quality control standards, our ability to enforce our intellectual
property rights, whether additional studies are released and
support the conclusions of past studies, whether ongoing patient
results with our products are favorable and in line with the
conclusions of clinical studies and initial patient results,
patient results achieved when our products are used for the
treatment of cancers and malignant diseases, successful completion
of future research and development activities, whether we, our
distributors and our customers will successfully obtain and
maintain all required regulatory approvals and licenses to market,
sell and use our products in its various forms, continued
compliance with ISO standards as audited by BSI, the success of our
sales and marketing efforts, changes in reimbursement rates,
changes in laws and regulations applicable to our products, and
other risks detailed from time to time in IsoRay's reports filed
with the SEC. Unless required to do so by law, the Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Logo - http://photos.prnewswire.com/prnh/20160301/339505LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isoray-inc-announces-launch-of-newly-redesigned-patient-and-clinician-focused-corporate-website-300335476.html
SOURCE IsoRay, Inc.